See the published version of this preprint at Nature Communications.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Article
Jan Cools
KU Leuven/VIB
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas with poor prognosis. Up to 30% of PTCL lack distinctive features and are classified as PTCL, not otherwise specified (PTCL-NOS). To further improve our understanding of the genetic landscape and biology of PTCL-NOS, we performed RNA-sequencing of 18 cases and validated results in an independent cohort of 37 PTCL cases. We identified FYN-TRAF3IP2, KHDRBS1-LCK and SIN3A-FOXO1 as new in-frame fusion transcripts, with FYN-TRAF3IP2 as a recurrent fusion detected in 8 of 55 cases. Using ex vivo and in vivo experiments, we demonstrate that FYN-TRAF3IP2 and KHDRBS1-LCK activate signaling pathways downstream of the T cell receptor (TCR) complex and confer therapeutic vulnerability to clinically available drugs.
Keywords
Peripheral T cell lymphoma (PTCL), non-Hodgkin lymphomas, T cell receptor (TCR)
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 9
Figure 10
There is NO Competing Interest.
This is a list of supplementary files associated with this preprint. Click to download.
- FigureS1.pdf
Suppl Figure S1
- FigureS2.pdf
Suppl Figure S2
- FigureS3.pdf
Suppl Figure S3
- FigureS4small.pdf
Suppl Figure S4
- FigureS5small.pdf
Suppl Figure S5
- FigureS6.pdf
Suppl Figure S6
- FigureS7.pdf
Suppl Figure S7
- SupplementaryTable1.xlsx
Suppl Table1
- SupplementaryTable2.xlsx
Suppl Table2
- KDBfusionsPTCLsupplementalrevisedfinal.docx
Supplemental data
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Nature Communications.
Version 1
Posted 05 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Nature Communications.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Article
Jan Cools
KU Leuven/VIB
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Nature Communications.
Version 1
Posted 05 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Nature Communications.
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas with poor prognosis. Up to 30% of PTCL lack distinctive features and are classified as PTCL, not otherwise specified (PTCL-NOS). To further improve our understanding of the genetic landscape and biology of PTCL-NOS, we performed RNA-sequencing of 18 cases and validated results in an independent cohort of 37 PTCL cases. We identified FYN-TRAF3IP2, KHDRBS1-LCK and SIN3A-FOXO1 as new in-frame fusion transcripts, with FYN-TRAF3IP2 as a recurrent fusion detected in 8 of 55 cases. Using ex vivo and in vivo experiments, we demonstrate that FYN-TRAF3IP2 and KHDRBS1-LCK activate signaling pathways downstream of the T cell receptor (TCR) complex and confer therapeutic vulnerability to clinically available drugs.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 9
Figure 10
There is NO Competing Interest.
This is a list of supplementary files associated with this preprint. Click to download.
- FigureS1.pdf
Suppl Figure S1
- FigureS2.pdf
Suppl Figure S2
- FigureS3.pdf
Suppl Figure S3
- FigureS4small.pdf
Suppl Figure S4
- FigureS5small.pdf
Suppl Figure S5
- FigureS6.pdf
Suppl Figure S6
- FigureS7.pdf
Suppl Figure S7
- SupplementaryTable1.xlsx
Suppl Table1
- SupplementaryTable2.xlsx
Suppl Table2
- KDBfusionsPTCLsupplementalrevisedfinal.docx
Supplemental data
Loading...